Following the appointment of Dr. Hans Moebius as Chief Medical Officer, TauRx has undertaken a competitive bid and review process to identify the most suitable partner to take forward its Phase 3 program. TauRx has now entered into an agreement with INC Research via a Letter of Intent [forming a broad Alliance] to initiate preparations for Phase 3 studies in mild and moderate AD, and also in orphan indications such as Fronto-Temporal Dementia and provisionally Progressive Supranuclear Palsy.